Compare RCON & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCON | TVRD |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 37.3M |
| IPO Year | 2009 | N/A |
| Metric | RCON | TVRD |
|---|---|---|
| Price | $1.63 | $3.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 23.0K | ★ 135.8K |
| Earning Date | 10-14-2025 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,252,775.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $3.74 |
| 52 Week High | $7.16 | $43.65 |
| Indicator | RCON | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 65.27 | 35.10 |
| Support Level | $1.24 | $3.90 |
| Resistance Level | $1.64 | $4.46 |
| Average True Range (ATR) | 0.13 | 0.25 |
| MACD | 0.04 | 0.16 |
| Stochastic Oscillator | 91.61 | 17.46 |
Recon Technology Ltd provides automation systems, industrial equipment, and support services tailored for the oil and gas industry in China. The company's business spans key segments such as automation products and software, equipment and accessories, oilfield environmental protection, and platform outsourcing services. It generates the majority of its revenue by providing integrated automation services to Chinese petroleum companies at oilfields. Its key products and services include pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system. The company's operations are centered on servicing upstream clients throughout China, with some broader industrial automation solutions.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.